Pascale Khairallah,Jenna Cherasard,Joshua C. Sung,Sanchita Agarwal,Maria Alejandra Aponte,Mariana Bucovsky,Maria Fusaro,Jeffrey Silberzweig,Gail N. Frumkin,Karim El Hachem,Linda Schulman,Donald J. McMahon,Matthew R. Allen,Corinne E. Metzger,Rachel K. Surowiec,Joseph M. Wallace,Thomas L. Nickolas
Secondary hyperparathyroidism is associated with osteoporosis and fractures. Etelcalcetide is an intravenous calcimimetic for the control of hyperparathyroidism in patients on hemodialysis. Effects of etelcalcetide on the skeleton are unknown.